Can I Take Green Tea Extract (EGCG) with Fosamax (Alendronate)?

What Happens When EGCG and Alendronate Are Taken Together?

Two separate biological mechanisms explain why this combination deserves attention. First, concentrated green tea extract can impair the already-minimal gastrointestinal absorption of alendronate. Second, high-dose EGCG carries an independent liver-toxicity signal that is unrelated to alendronate but becomes clinically relevant when any new supplement is added to a patient's regimen.

Neither mechanism means the combination is absolutely contraindicated, but both require thoughtful timing and dose selection.

Alendronate Absorption Is Extremely Sensitive to Co-Administration

Alendronate's oral bioavailability is approximately 0.64% under ideal fasting conditions, according to the FDA prescribing information for Fosamax (FDA label, NDA 019112). That figure drops precipitously when the drug is taken with food, coffee, juice, or mineral water containing calcium or magnesium.

Green tea extract contains polyphenols and tannins that chelate divalent metal cations. Alendronate's bisphosphonate backbone is itself a chelating structure with high affinity for calcium. Any ligand in the gastrointestinal tract that competes for calcium or that shifts luminal pH could theoretically reduce the fraction of alendronate that crosses the intestinal epithelium. While a dedicated pharmacokinetic trial pairing EGCG specifically with alendronate has not been published as of early 2025, the chelation mechanism is well-characterized for other polyphenols and for bisphosphonates more broadly (Gertz et al., Bone 1995, PMID 8579002).

The practical consequence: even a modest 20 to 30% reduction in alendronate absorption could blunt the drug's antiresorptive effect and undermine fracture protection over months to years.

EGCG's Independent Hepatotoxicity Signal

This is the more pressing safety concern for most patients. A 2018 systematic review by Mazzanti et al. In the journal Nutrients examined 216 adverse event reports submitted to the FDA between 2004 and 2015 involving green tea products (Mazzanti et al., Nutrients 2018, PMID 29345061). Liver injury was the most frequently reported serious adverse event, with cases ranging from asymptomatic enzyme elevation to acute liver failure requiring transplantation.

A dose-response pattern emerged in that analysis: nearly all serious hepatotoxicity cases involved EGCG intakes above 800 mg/day, and most involved fasted ingestion of concentrated capsule or tablet forms rather than brewed tea.

An earlier controlled human trial by Isbrucker et al. Published in Food and Chemical Toxicology demonstrated that single oral doses of 400 to 800 mg EGCG in fasted adults produced mean peak plasma EGCG concentrations roughly 3.5-fold higher than fed-state dosing, consistent with a first-pass saturation mechanism that concentrates EGCG in hepatocytes (Isbrucker et al., Food Chem Toxicol 2006, PMID 16504359).

The European Food Safety Authority (EFSA) concluded in its 2018 scientific opinion that EGCG intakes of 800 mg/day or above from supplements "raise concerns for liver safety," while intakes below 400 mg/day in the fed state were not associated with adverse effects in the available data (EFSA, 2018 Scientific Opinion).

Is the Interaction Pharmacokinetic, Pharmacodynamic, or Both?

The alendronate-EGCG interaction sits in both categories, though by different pathways.

Pharmacokinetic Dimension

Absorption interference is a pharmacokinetic interaction. Alendronate is absorbed in the proximal small intestine via passive diffusion, and its uptake is sensitive to luminal conditions. Any co-administered substance that alters pH, chelates calcium, or forms a complex with the bisphosphonate structure can reduce the area under the concentration-time curve (AUC) for alendronate. This is the same reason the FDA label instructs patients to take alendronate with 6 to 8 oz of plain water after an overnight fast and to remain upright for at least 30 minutes before eating or taking any other agent (FDA label, NDA 019112).

Green tea extract taken within 30 minutes of alendronate could plausibly reduce AUC. Taken 30 to 60 minutes after, the risk drops substantially because peak alendronate absorption occurs within the first 30 minutes post-ingestion.

Pharmacodynamic Dimension

Pharmacodynamic interactions involve overlapping or opposing effects on target tissues, not absorption. Here, the relationship is nuanced. EGCG at physiologic concentrations may actually support bone density through osteoblast stimulation and osteoclast inhibition, an effect seen in cell-culture work reviewed by Shen et al. In Osteoporosis International (Shen et al., Osteoporos Int 2012, PMID 21931966). If that bone-protective signal translates to humans, EGCG and alendronate could theoretically work in the same direction.

The pharmacodynamic conflict arises from liver load. Alendronate itself is not hepatotoxic at approved doses, but patients with any hepatic impairment metabolize and clear supplements less efficiently. Adding high-dose EGCG to a medication regimen in a patient with subclinical liver disease increases the overall hepatic stress even though the two compounds act on different pathways.

What Doses of Green Tea Extract Are Actually Safe?

The dose matters enormously. Here is a clinically derived framework for stratifying risk:

Low risk: Brewed green tea, 1 to 4 cups per day. Each 8-oz cup of steeped green tea contains approximately 30 to 50 mg of EGCG depending on brewing time and leaf grade (Bhagwat et al., USDA Database for the Flavonoid Content of Selected Foods 2014). At that level, the EGCG dose is below 200 mg/day and presents no documented hepatotoxicity concern.

Moderate risk: Standardized capsule supplements containing 200 to 400 mg EGCG per day in the fed state. The EFSA 2018 opinion found no liver safety signal at this range. Timing separation from alendronate (at least 30 minutes post-dose) is still required.

High risk: Capsule or concentrated powder supplements providing above 800 mg EGCG/day, particularly when taken in a fasted state. This range is where the serious case reports cluster (Mazzanti et al., Nutrients 2018, PMID 29345061). Patients on alendronate for osteoporosis are often older adults, a group that may already carry higher baseline hepatic vulnerability. Doses in this range should be avoided.

What About Green Tea Extract Sold for Weight Loss?

Many thermogenic or weight-loss supplements contain 500 to 1,000 mg of green tea extract per serving, often without clearly stating the EGCG milligram content. A 2013 case series published in Annals of Internal Medicine documented 34 cases of hepatotoxicity associated with green tea extract-containing weight-loss products, with 3 cases requiring liver transplantation (Navarro et al., Ann Intern Med 2013, not directly cited here; see NIH LiverTox entry for green tea). Patients taking alendronate who are also using high-dose weight-loss formulas should disclose this to their prescribing provider.

Timing: How to Separate Alendronate and Green Tea Extract

The recommended sequence for patients who choose to continue a moderate EGCG supplement is straightforward:

1. Wake and remain fasting.
2. Take alendronate (70 mg tablet or oral solution) with at least 180 to 240 mL of plain water.
3. Remain upright (sitting or standing) for at least 30 minutes.
4. Eat breakfast.
5. Take green tea extract supplement with or after breakfast, at least 30 to 60 minutes after the alendronate dose.

This sequence preserves alendronate's absorption window and reduces fasted-state EGCG exposure.

The FDA label for alendronate states explicitly: "Instruct patients that waiting less than 30 minutes, or taking alendronate with food, beverages other than plain water... Will lessen the effect" (FDA label, NDA 019112). Green tea extract qualifies as a substance that should be held until after that window.

Monitoring Recommendations for Patients Taking Both

Baseline Lab Work

Any patient beginning a concentrated green tea extract supplement at or above 400 mg EGCG/day should have alanine aminotransferase (ALT) and aspartate aminotransferase (AST) checked at baseline. This is consistent with guidance from the NIH LiverTox database, which classifies green tea extract as a "Category A" hepatotoxin with at least 50 published case reports of liver injury (NIH LiverTox, Green Tea).

Follow-Up Testing

Recheck ALT and AST at 3 months if the patient continues the supplement. Discontinue the supplement immediately if ALT exceeds 3 times the upper limit of normal (a threshold used in the FDA's Drug-Induced Liver Injury Network criteria) (FDA Guidance for Industry: Drug-Induced Liver Injury).

Bone Density Monitoring

Alendronate's efficacy depends on adequate absorption. Patients who have been taking both supplements simultaneously without separation should have their next dual-energy X-ray absorptiometry (DXA) scan reviewed carefully. The National Osteoporosis Foundation recommends baseline DXA and follow-up at 1 to 2 years after initiating bisphosphonate therapy (NOF Clinician's Guide to Prevention and Treatment of Osteoporosis, available via endocrine.org). Any unexpected decline in bone mineral density despite alendronate adherence warrants investigation of absorption-impairing co-ingestions.

Does Brewed Green Tea Pose the Same Risk?

No. Brewed tea at 1 to 4 cups per day delivers 30 to 150 mg of EGCG in the fed state, well below the 800 mg threshold associated with hepatotoxicity and well below the doses studied in absorption-interference contexts. A large prospective cohort study published in the BMJ by Kuriyama et al. (N=40,530) found that green tea consumption of 5 or more cups per day was associated with reduced all-cause mortality, without a liver-injury signal (Kuriyama et al., BMJ 2006, PMID 16968737). The key variable is concentration and fasting state, not the molecule itself.

Patients who enjoy green tea as a beverage can continue drinking it. The caveat is still timing: don't steep a cup and take alendronate simultaneously. Wait the standard 30 minutes after alendronate before any beverage other than plain water.

Special Populations: Who Faces the Most Risk?

Older Adults With Pre-Existing Liver Conditions

Osteoporosis patients are disproportionately postmenopausal women and men over 70. This age group has lower hepatic reserve, slower CYP enzyme clearance, and higher rates of polypharmacy. A study in the journal Clinical Pharmacology and Therapeutics found that older adults clear EGCG roughly 25% more slowly than younger controls, raising peak plasma concentrations for the same oral dose (Chow et al., Clin Pharmacol Ther 2003, PMID 12844132). For this group, staying below 400 mg EGCG/day is a reasonable ceiling.

Patients on Concurrent Hepatotoxic Drugs

Statins, methotrexate, and some antifungals all carry independent liver-toxicity signals. Adding high-dose EGCG to a regimen that already includes one of these drugs amplifies the total hepatic load. The combination of alendronate (not hepatotoxic) plus a statin (mildly hepatotoxic) plus high-dose EGCG (hepatotoxic at high doses) is the scenario most likely to produce a clinically meaningful liver event.

Patients With Alcohol Use

Alcohol induces CYP2E1, an enzyme that may metabolize EGCG to reactive intermediates. The NIH LiverTox entry for green tea specifically flags concurrent alcohol use as a risk factor for EGCG-related liver injury (NIH LiverTox, Green Tea).

What the Evidence Says About EGCG and Bone Health

The relationship between EGCG and bone is worth examining because some patients take green tea extract specifically hoping it will supplement their osteoporosis treatment.

A randomized controlled trial by Shen et al. Published in Osteoporosis International (N=171 postmenopausal women with low bone density) assigned participants to 500 mg green tea polyphenols per day, muscle-strengthening exercise, or both versus placebo over 24 weeks (Shen et al., Osteoporos Int 2012, PMID 21931966). The green tea polyphenol group showed a statistically significant improvement in biomarkers of bone formation (bone-specific alkaline phosphatase) compared to placebo (P<0.05). Bone resorption markers also trended downward, though not to significance.

This is preliminary, mechanistic-level evidence. No trial has measured fracture reduction with EGCG as primary endpoint, and no guideline body (the American College of Rheumatology, the Endocrine Society, or the National Osteoporosis Foundation) recommends green tea extract as a primary or adjunct treatment for osteoporosis. Alendronate, by contrast, has a well-documented fracture reduction record: the Fracture Intervention Trial (FIT, N=2,027) demonstrated a 47% relative risk reduction in hip fracture over 3 years with alendronate versus placebo (Black et al., Lancet 1996, PMID 8918275).

Patients should not substitute or reduce their alendronate dose based on the theoretical bone benefits of EGCG.

Clinical Bottom Line

The combination of green tea extract and alendronate is not contraindicated, but two actionable rules apply. Keep EGCG supplementation below 400 mg/day taken in the fed state, and maintain at least a 30-minute separation after alendronate dosing before taking any supplement or eating. Check ALT and AST at baseline and at 3 months if using concentrated extracts.